Sanofi's Kevzara Phase 3 Trial for Covid-19 Failed to Meet Primary Endpoint

By Giulia Petroni

Sanofi SA said Tuesday the Phase 3 trial investigating the use of Kevzara in severely or critically ill Covid-19 patients didn't meet its primary endpoint and key secondary endpoint.

The 420-patient randomized trial, which was conducted outside the U.S., was investigating the administration of Kevzara intravenously at a dose of 200 milligrams or 400 milligrams, the French pharmaceutical company said.

Sanofi and Regeneron Pharmaceuticals Inc. aren't planning to conduct further clinical studies for the use of Kevzara in patients affected by Covid-19, the company said.

Kevzara is a treatment for adults with moderate to severe active rheumatoid arthritis who haven't responded to or tolerated previous therapy.

Write to Giulia Petroni at giulia.petroni@wsj.com

(END) Dow Jones Newswires

September 01, 2020 01:37 ET (05:37 GMT)

Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Mar 2024 to Apr 2024